ABVC BioPharma (ABVC) Proxy Filing summary

Executive summary

• The proxy filing covers the 2025 annual meeting, including board elections, auditor ratification, related party transactions, and amendments to the equity incentive plan.

• The company is a clinical-stage biopharmaceutical firm focused on plant-derived drugs and medical devices, with a pipeline in CNS, oncology, and ophthalmology.

• Recent operations include licensing agreements, collaborative R&D, and ongoing efforts to improve liquidity and reduce debt.

• The company faces substantial doubt about its ability to continue as a going concern due to recurring losses and working capital deficits.

Voting matters and shareholder proposals

• Shareholders will vote on re-electing 11 director nominees for one-year terms.

• Ratification of Simon & Edward, LLP as the independent auditor for 2025 is proposed.

• Approval is sought for a related party land purchase from a director, potentially issuing shares exceeding 20% of outstanding stock.

• Proposal to increase the 2016 Equity Incentive Plan to 15% of outstanding shares, with annual 5% increases until the cap is reached.

Board of directors and corporate governance

• The board consists of 11 directors, with a majority classified as independent under NASDAQ rules.

• Key committees (Audit, Compensation, Nominating) are composed of independent directors.

• The board oversees risk management, with management responsible for day-to-day risk processes.

• Family relationships exist among several directors, and there are cross-directorships with related entities.